Genotoxic exposure is associated with alterations in glucose uptake and metabolism.
Recent observations suggest that growth factor withdrawal can promote cell death in part through modulation of basic cellular bioenergetic pathways, including inhibition of glucose uptake and glycolytic metabolism. Whether DNA damage-initiated cell death pathways also involve bioenergetic deregulation has not been studied previously. Subtractive suppressive hybridization was used to identify changes in gene expression in murine cells after exposure to genotoxic stimuli, including cisplatin, etoposide, and gamma-radiation. Among the genes identified in this screen were several that regulate glycolytic metabolism. Enzymes that catalyze key regulatory steps of glycolysis, including hexokinase, phosphofructokinase, and pyruvate kinase, appeared to be coordinately down-regulated by genotoxic exposure. Northern blotting confirmed that these changes in gene expression occur within 4 h of exposure to several DNA-damaging agents. Genotoxic exposure was found to similarly inhibit expression of both glut-1 and glut-3, genes that encode critical regulators of glucose uptake. Direct measurement of glycolytic rate and of oxygen consumption confirmed that genotoxic exposure resulted in suppression of both anaerobic and aerobic metabolism. Many of these metabolic changes mimic those observed after growth factor withdrawal. Together, these observations suggest that multiple apoptotic triggers, including growth factor withdrawal and genotoxic exposure, suppress cellular bioenergetic pathways. Mitochondrial responses to the resulting rapid decrease in metabolic substrates may play an important role in initiation of apoptotic cell death.
Zhou
Rixin
R
Department of Medicine and the Committee on Cancer Biology, University of Chicago, Illinois 60637, USA.
Vander Heiden
Matthew G
MG
Rudin
Charles M
CM
D000818:Animals; D002460:Cell Line; D002945:Cisplatin / Q000633:toxicity; D004249:DNA Damage; D015536:Down-Regulation / Q000187:drug effects / Q000528:radiation effects; D005047:Etoposide / Q000633:toxicity; D005720:Gamma Rays / Q000009:adverse effects; D005787:Gene Frequency / Q000187:drug effects / Q000528:radiation effects; D005947:Glucose / Q000378:metabolism* / Q000493:pharmacokinetics; D051272:Glucose Transporter Type 1; D051274:Glucose Transporter Type 3; D006019:Glycolysis / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects; D051379:Mice; D009004:Monosaccharide Transport Proteins / Q000096:biosynthesis / Q000235:genetics; D009153:Mutagens / Q000633:toxicity*; D009419:Nerve Tissue Proteins; D010084:Oxidation-Reduction
D051272:Glucose Transporter Type 1; D051274:Glucose Transporter Type 3; D009004:Monosaccharide Transport Proteins; D009153:Mutagens; D009419:Nerve Tissue Proteins; C495678:Slc2a1 protein, mouse; C495689:Slc2a3 protein, mouse; D005047:Etoposide; D005947:Glucose; D002945:Cisplatin